Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9867722 | 0.78 | ALDH1A1 (0.33) | POLBCA1CA2 | |
| SCHEMBL17323652 | 0.77 | POLB (0.42) | POLBCYP2C19 | |
| SCHEMBL3466455 | 0.76 | ALDH1A1 (0.38) | POLBCA1CA2CYP2C19 | |
| SCHEMBL7478797 | 0.75 | POLB (0.40) | POLBCYP2C19 | |
| Hydrochloric Acid SCHEMBL5498553 | 0.74 | ALDH1A1 (0.36) | — | |
| SCHEMBL11100542 | 0.74 | APEX1 (0.52) | FFAR3PHF8KDM2AAPEX1KDM6B | |
| SCHEMBL28069326 | 0.72 | POLB (0.48) | POLBAPEX1CYP2C19MMP2MMP7 | |
| SCHEMBL23571252 | 0.72 | — | — | |
| SCHEMBL4543902 | 0.72 | TSHR (0.42) | CA1CA2 | |
| SCHEMBL10732276 | 0.70 | CA1 (0.31) | CA1CA2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2049494-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8222269-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090203684-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| EP-2049494-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090012076-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2009-01-08 | — | — | US | disclosed |
| WO-2008008310-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-3960853-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
| US-3960852-A | BACTERICIDES | SMITHKLINE BECKMAN CORPORATION | 1976-06-01 | — | — | US | disclosed |
| US-3960855-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
| US-3948905-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
| US-3939266-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | POLB 1777/4885FFAR3 4844/4885PHF8 3247/4885 |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | POLB 156/4885FFAR3 4022/4885PHF8 867/4885 |
| US-20090012076-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, MET | POLB 1947/4885FFAR3 2530/4885PHF8 1062/4885 |
| US-20090203684-A1 | Tyrosine kinase inhibitors | ABL1, MET, ERBB2 | POLB 1694/4885FFAR3 2281/4885PHF8 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.